Personal Finance

Why Portola Pharmaceuticals Skyrocketed 25.6% Today

A man in a dress shirt and vest pumps his arms upward while smiling.

What happened

After the management reported that the U.S. Food and Drug Administration granted approval for its anticoagulant-reversal antidote, AndexXa, shares of Portola Pharmaceuticals (NASDAQ: PTLA) jumped by 25.6% on Friday.

So what

Portola Pharmaceuticals' AndexXa acts as a decoy for a class of anticoagulants called factor Xa inhibitors that are increasingly being used in place of Warfarin to prevent stroke, pulmonary embolism, and venous thromboembolism (VTE).

A man in a dress shirt and vest pumps his arms upward while smiling.

IMAGE SOURCE: GETTY IMAGES.

AndexXa has been in development for years, and today's FDA approval was far from guaranteed given that the regulator previously rejected its approval in August 2016, citing a need for more data demonstrating its ability to reverse factor Xa inhibitory activity.

Portola Pharmaceuticals resubmitted AndexXa's application for approval last year; however, the prospects for an approval dimmed in December when the FDA pushed back its approval decision date by 90 days so that it could review interim data from Portola Pharmaceuticals' ongoing Anexxa 4 study.

AndexXa's approval is significant because there are over 100,000 hospital admissions and 2,000 deaths in the U.S. per month because of bleeding events in patients taking factor Xa inhibitors. The approval provides healthcare providers with the first medicine that's specifically designed to restore clotting in these patients, so there's a good chance that demand will ramp quickly for it.

Now what

The approval is the second green light that Portola Pharmaceuticals has received in the past year. The first approval was for Bevyxxa, a factor Xa anticoagulant that won FDA approval as an alternative to Lovenox for use in adult patients hospitalized for an acute illness.

Bevvyxa only launched in January, so it remains to be seen if it will be a commercial success, but there's reason for optimism. The market share-leading factor Xa inhibitors, Xarelto and Eliquis, generate a combined $5 billion per year in sales and, prior to losing its patent protection, Lovenox generated sales greater than $2 billion annually.

AndexXa's approval to reverse the effects of drugs like Xarelto and Eliquis could translate into hundreds of millions of dollars or more in annual sales, so combined, Portola Pharmaceuticals' two drugs have the potential to turn it into a much larger company. Given that opportunity, adding Portola Pharmaceuticals shares to portfolios could be savvy.

10 stocks we like better than Portola Pharmaceuticals

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has quadrupled the market.*

David and Tom just revealed what they believe are the 10 best stocks for investors to buy right now... and Portola Pharmaceuticals wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of April 2, 2018

Todd Campbell owns shares of Portola Pharmaceuticals. His clients may have positions in the companies mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Other Topics

Stocks

Latest Personal Finance Videos

Black Friday Brings Higher Demand and Scarcer Deals

Nov 26, 2021

The Motley Fool

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Learn More